Cost Comparison in the Management of the Renal Cell Carcinoma with in Spain: Pazopanib vs. Sunitinib
Value in Health2016Vol. 19(7), pp. A721–A721
Related Papers
- → Improvement of Psoriasis During Sunitinib Therapy for Renal Cell Carcinoma(2010)33 cited
- → [Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib].(2015)3 cited
- → One year survivor of metastatic renal cell carcinoma treated with pazopanib(2017)1 cited
- → Cost Comparison in the Management of the Renal Cell Carcinoma with in Spain: Pazopanib vs. Sunitinib(2016)
- → Comparison of First-line Pazopanib and Sunitinib in Metastatic Renal Cell Carcinoma: Experiences of the Urologic Cancer Centre for Research and Innovation(2019)